Bank Of Montreal Aquestive Therapeutics, Inc. Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Aquestive Therapeutics, Inc. stock. As of the latest transaction made, Bank Of Montreal holds 49,301 shares of AQST stock, worth $187,343. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,301

Previous 14,300 244.76%

Holding current value

$187,343

Previous $37,000 562.16%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.4 - $5.09 $84,002 - $178,155	35,001 Added 244.76%	49,301 $245,000
Q1 2024 May 13, 2024	SELL	$2.01 - $6.09 $8,904 - $26,978	-4,430 Reduced 23.65%	14,300 $60,000
Q4 2023 Feb 08, 2024	SELL	$1.29 - $2.47 $645 - $1,235	-500 Reduced 2.6%	18,730 $37,000
Q2 2023 Aug 02, 2023	SELL	$1.06 - $2.49 $1,590 - $3,735	-1,500 Reduced 7.24%	19,230 $31,000
Q1 2023 Jun 13, 2024	BUY	$0.72 - $1.15 $3,549 - $5,669	4,930 Added 34.48%	19,230 $21,000
Q4 2022 Feb 01, 2023	BUY	$0.77 - $1.18 $2,310 - $3,540	3,000 Added 16.92%	20,730 $18,000
Q3 2022 Nov 10, 2022	BUY	$0.63 - $1.73 $334 - $918	531 Added 3.09%	17,730 $21,000
Q2 2022 Aug 11, 2022	BUY	$0.64 - $2.57 $3,468 - $13,929	5,420 Added 46.01%	17,199 $15,000
Q1 2022 May 12, 2022	SELL	$2.28 - $4.26 $16,007 - $29,909	-7,021 Reduced 37.35%	11,779 $34,000
Q4 2021 Feb 11, 2022	SELL	$3.69 - $6.37 $10,774 - $18,600	-2,920 Reduced 13.44%	18,800 $75,000
Q3 2021 Nov 12, 2021	BUY	$3.25 - $4.66 $2,275 - $3,262	700 Added 3.33%	21,720 $96,000
Q2 2021 Aug 12, 2021	BUY	$3.29 - $5.21 $69,155 - $109,514	21,020 New	21,020 $87,000

Others Institutions Holding AQST

# of Institutions

122

Shares Held

46.8M

Call Options Held

517K

Put Options Held

207K

View Full List

About Aquestive Therapeutics, Inc.

Ticker AQST
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,350,700
Market Cap $203M
Description
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual f...

More about AQST

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account